We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Online ordering will be unavailable from 17:00 GMT on Friday, April 25 until 17:00 GMT on Sunday, April 27 due to maintenance. We apologise for the inconvenience.
Hostname: page-component-669899f699-8p65j
Total loading time: 0
Render date: 2025-04-25T22:16:23.438Z
Has data issue: false
hasContentIssue false
Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
T. Khadem*
Affiliation:
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
M. Hong Nguyen
Affiliation:
Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
*
Author for correspondence: J. Ryan Bariola, MD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: [email protected]. Or T. Khadem, PharmD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: [email protected]
Author for correspondence: J. Ryan Bariola, MD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: [email protected]. Or T. Khadem, PharmD, 3601 Fifth Avenue, Suite 3A, Pittsburgh PA 15213. Email: [email protected]
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Article purchase
Temporarily unavailable
Footnotes
PREVIOUS PRESENTATION. This study was presented as an abstract at ID Week 2018 on October 6, 2018 in San Francisco, California.
References
1
Schulz, LT, Kim, SY, Hartsell, A, Rose, WE. Antimicrobial stewardship during a time of rapid antimicrobial development: potential impact on industry for future investment. Diagn Microbiol Infect Dis2019. pii: S0732-8893(19)30344-X. Advance online publication.Google Scholar
2
Shields, RK, Potoski, BA, Haidar, G, et al.Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis2016;63:1615–1618.CrossRefGoogle ScholarPubMed
3
Gelfand, MS, Cleveland, KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa.Clin Infect Dis2015;61:853–855.CrossRefGoogle ScholarPubMed
4
Delaportas, DJ, Estrada, SJ, Darmelio, M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy2017;37:e90–e92.CrossRefGoogle ScholarPubMed
5
Shields, RK, Nguyen, MH, Chen, L, Press, EG, Kreiswirth, BN, Clancy, CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infection. Antimicrob Agent Chemother2018;62:e02497–17.CrossRefGoogle Scholar
6
Plant, AJ, Dunn, A, Porter, RJ. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Psuedomonas aeruginosa pneumonia. Expert Rev Anti Infect Ther2018;16:367–368.CrossRefGoogle Scholar
7
Cox, E, Nambiar, S, Badan, L. Needed: antimicrobial development. New Eng J Med2019;380:783–785.CrossRefGoogle ScholarPubMed